Les vaccins de l’adulte : un pilier sous-estimé de la prévention des maladies cardiovasculaires.

Cardiovascular disease; Infection; Prevention; Vaccines; COVID-19 Vaccines; Influenza Vaccines; Pneumococcal Vaccines; Humans; Adult; Influenza Vaccines/immunology; Cardiovascular Diseases/prevention & control; COVID-19/prevention & control; COVID-19/immunology; Cardiovascular Diseases; COVID-19; Medicine (all)

Abstract :

[en] This brief article focuses on vaccines targeted against five infectious agents that are linked to an increased cardiovascular risk in adults: COVID-19, influenza, pneumococcus, respiratory syncytial virus, and varicella-zoster virus. The article is divided into three parts. Firstly, it outlines the mechanisms responsible for cardiovascular events that occur during and after infections. Secondly, it discusses the principles of vaccine protection in this context. The third part is dedicated to clinical studies that specifically demonstrate the cardiovascular protection afforded by the vaccines. Vaccines targeting the five aforementioned infectious agents should undoubtedly be considered key elements in the prevention of cardiovascular risk.
[fr] Ce bref article est consacré aux vaccins dirigés contre cinq agents infectieux impliqués dans un accroissement du risque cardiovasculaire de l’adulte : COVID-19, influenza, pneumocoque, virus respiratoire syncytial et virus varicelle-zona. L’article est divisé en trois parties. Nous rappelons d’abord les mécanismes responsables des événements cardiovasculaires qui surviennent pendant et après les infections. Nous abordons ensuite les principes de la protection vaccinale en la matière. La troisième partie est consacrée à des études cliniques qui démontrent spécifiquement la protection cardiovasculaire conférée par les vaccins. Les vaccins dirigés contre les cinq agents infectieux cités plus haut devraient indiscutablement être considérés comme des éléments-clés de la prévention du risque cardiovasculaire.

Disciplines :

Immunology & infectious disease

Author, co-author :

Moutschen, Michel ; Université de Liège - ULiège > GIGA > GIGA Immunobiology - Immunology & Infectious Diseases

Language :

French

Title :

Les vaccins de l’adulte : un pilier sous-estimé de la prévention des maladies cardiovasculaires.

Alternative titles :

[en] Vaccines in adults : an underestimated pillar of cardiovascular disease prevention.

Publication date :

2024

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Revue Medicale de Liege, Belgium

Volume :

Issue :

5-6

Pages :

277 - 281

Peer reviewed :

Editorial Reviewed verified by ORBi

Available on ORBi :

since 12 June 2025

Statistics

Number of views

36 (0 by ULiège)

Number of downloads

28 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

The WHO European Respiratory Surveillance Network. Estimated number of lives directly saved by COVID-19 vaccination programs in the WHO European Region, December 2020 to March 2023 [Internet]. 2024 [cité 6 mai 2024]. Disponible sur: http://medrxiv.org/lookup/doi/10.1101/2024.01.12.24301206
Parums DV. A review of the resurgence of measles, a vaccine-preventable disease, as current concerns contrast with past hopes for measles elimination. Med Sci Monit Int 2024;30:e944436.
Vallet-Pichard A, Pol S. Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma. Aliment Pharmacol Ther 2021;53:1166-82.
Hernández-Silva CD, Ramírez de Arellano A, Pereira-Suárez AL, Ramírez-López IG. HPV and cervical cancer: molecular and immunological aspects, epidemiology and effect of vaccination in latin american women. Viruses 2024;16:327.
García-Zamora S, Pulido L. Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk. Arch Peru Cardiol Cirugia Cardiovasc 2024;5:29-39.
Rademacher J, Therre M, Hinze CA, et al. Association of respiratory infections and the impact of vaccinations on cardiovascular diseases. Eur J Prev Cardiol 2024;zwae016.
Linder M, Müller-Berghaus G, Lasch HG, Gagel C. Virus infection and blood coagulation. Thromb Diath Haemorrh 1970;23:1-11.
Haeck G, Ancion A, Marechal P, et al. COVID-19 et maladies cardiovasculaires. Rev Med Liege 2020;75 (Suppl):226-32.
Iba T, Levy JH, Maier CL, et al. Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned ? J Thromb Haemost 2024;S1538-7836 (24) 00115-6.
Lee YJ, Park G, Lee SG, et al. Predictive value of plaque characteristics for identification of lesions causing ischemia. Int J Cardiol 2024;406:132097.
Gianopoulos I, Daskalopoulou SS. Macrophage profiling in atherosclerosis: understanding the unstable plaque. Basic Res Cardiol 2024;119:35-56.
Eberhardt N, Noval MG, Kaur R, et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat Cardiovasc Res 2023;2:899-916.
Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022;28:583-90.
Peters P, Sprynger M, Lancellotti P, Oury C. Coagulopathies, risque thrombotique et anticoagulation dans la COVID-19. Rev Med Liege 2020;75 (Suppl):86-93.
Muñoz-Quiles C, López-Lacort M, Urchueguía A, et al. Risk of cardiovascular events after influenza: a population-based self controlled case series study, Spain 2011-2018. J Infect Dis 2024;jiae070.
Woodruff RC, Melgar M, Pham H, et al. Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection. JAMA Intern Med 2024;e240212.
Lu P, Cui L, Zhang X. Stroke risk after varicella-zoster virus infection: a systematic review and meta-analysis. J Neurovirol 2023;29:449-59.
Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis Off Publ Infect Dis Soc Am 2007;45:158-65.
Anderson R, Feldman C. The global burden of community-acquired pneumonia in adults, encompassing invasive pneumococcal disease and the prevalence of its associated cardiovascular events, with a focus on pneumolysin and macrolide antibiotics in pathogenesis and therapy. Int J Mol Sci 2023;24:11038.
Alhamdi Y, Neill DR, Abrams ST, et al. Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLoS Pathog 2015;11:e1004836.
Junqueira C, Crespo Â, Ranjbar S, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 2022;606:576-84.
Mink S, Drexel H, Leiherer A, et al. Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study. Int J Infect Dis 2024;143:107016.
Kim YE, Huh K, Park YJ, et al. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA 2022;328:887-9.
Jiang J, Chan L, Kauffman J, et al. Impact of vaccination on major adverse cardiovascular events in patients with COVID-19 infection. J Am Coll Cardiol 2023;81:928-30.
Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. FLU vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 2004;25:25-31.
Fröbert O, Götberg M, Erlinge D, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation 2021;144:1476-84.
Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc 2021;10:e019636.
Africano HF, Serrano-Mayorga CC, Ramirez-Valbuena PC, et al. Major adverse cardiovascular events during invasive pneumococcal disease are serotype dependent. Clin Infect Dis 2021;72:e711-9.
Scheen AJ, Louis R, Lancellotti P, et al. Vaccination antipneumococcique dans les groupes à risque avec comorbidités: recommandations du Conseil Supérieur de la Santé et critères de remboursement. Rev Med Liege 2023;78:665-73.
Marques Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes 2021;7:97-106.
Hung IFN, Leung AYM, Chu DWS, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010;51:1007-16.
Aceil J, Avci FY. Pneumococcal surface proteins as virulence factors, immunogens, and conserved vaccine targets. Front Cell Infect Microbiol 2022;12:832254.
Feldman RG, Antonelli-Incalzi R, Steenackers K, et al. Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions. Clin Infect Dis 2024;78:202-9.
Yamaoka-Tojo M, Tojo T. Herpes Zoster and cardiovascular disease: exploring associations and preventive measures through vaccination. Vaccines 2024;12:252.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019-32.
Zerbo O, Bartlett J, Fireman B, et al. Effectiveness of recombinant Zoster vaccine against Herpes Zoster in a real-world setting. Ann Intern Med 2024;177:189-95.
Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8.
Azarpanah H, Farhadloo M, Vahidov R, Pilote L. Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases. BMC Public Health 2021;21:1686.